MediWound Ltd. announced the initiation of a new clinical development program to evaluate its drug product candidate MWPC005 in patients with non-melanoma skin cancer.
[MediWound Ltd.]
6606345
{6606345:nan}
apa
50
1
159516
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
